Cholesterol Uptake Capacity as a Prognostic Marker of Cardiovascular Events for Patients with Coronary Artery Disease
- PMID: 40159248
- PMCID: PMC12416930
- DOI: 10.5551/jat.65520
Cholesterol Uptake Capacity as a Prognostic Marker of Cardiovascular Events for Patients with Coronary Artery Disease
Abstract
Aim: Cholesterol uptake capacity (CUC) is a functional assessment of high-density lipoprotein (HDL) and has drawn attention for the risk stratification of atherosclerotic cardiovascular disease (ASCVD). This study evaluated the usefulness of HDL-CUC as a predictive marker for long-term ASCVD events in patients with coronary artery disease (CAD).
Methods: This retrospective observational study included 503 patients with CAD who underwent coronary revascularization. Blood was sampled from the participants within three months before or after index revascularization. The CUC was assayed using a previously reported automated system. The study population was divided into three groups according to the tertiles of CUC levels. The primary outcome was ASCVD events, which were defined as a composite of all-cause death, acute myocardial infarction, stroke, and peripheral artery disease.
Results: A total of 29 events were observed during the follow-up (median 2.8 years). The risk of the primary outcome in the low-CUC group was significantly higher than that in the high-CUC group (3-year incidence: low CUC 8.8% vs. high CUC 4.0%; log-rank p = 0.046). After adjusting for age and sex, the risk in the low-CUC group relative to that in the high-CUC group remained significantly high (hazard ratio 3.17, 95% confidence interval 1.05-9.54, p = 0.040).
Conclusion: Low CUC in patients with CAD were associated with a higher risk of ASCVD events after coronary revascularization than high CUC levels. The assessment of HDL functionality measured by CUC would be useful for the risk prediction of ASCVD after coronary revascularization.
Keywords: Cholesterol efflux capacity; Cholesterol uptake capacity; Coronary artery disease; Functionality of high-density lipoprotein; High-density lipoprotein; Secondary prevention.
Conflict of interest statement
The authors declare the following financial interests/personal relationships that may be considered potential competing interests. Ryuji Toh, Manabu Nagao, and Ken-ichi Hirata belong to the Division of Evidence-based Laboratory Medicine, Kobe University Graduate School of Medicine, which developed the CUC measurement assay and was established by an endowment fund from the Sysmex Corporation. However, there is no declaration of a consultant or advisory role, stock ownership, honoraria, expert testimony, or patent. Katsuhiro Murakami, Amane Harada, Jeeeun Kim, Yuto Kobayashi, and Keiko Miwa are employees of Sysmex Corporation. The other authors have no known competing financial interests or personal relationships to declare.
Figures




References
-
- Wilson PW, Abbott RD, Castelli WP. High density lipoprotein cholesterol and mortality. The Framingham Heart Study. Arteriosclerosis, 1988; 8: 737-741 - PubMed
-
- Madsen CM, Varbo A, Nordestgaard BG. Extreme high high-density lipoprotein cholesterol is paradoxically associated with high mortality in men and women: two prospective cohort studies. Eur Heart J, 2017; 38: 2478-2486 - PubMed
-
- Lincoff AM, Nicholls SJ, Riesmeyer JS, Barter PJ, Brewer HB, Fox KAA, Gibson CM, Granger C, Menon V, Montalescot G, Rader D, Tall AR, McErlean E, Wolski K, Ruotolo G, Vangerow B, Weerakkody G, Goodman SG, Conde D, McGuire DK, Nicolau JC, Leiva-Pons JL, Pesant Y, Li W, Kandath D, Kouz S, Tahirkheli N, Mason D, Nissen SE, ACCELERATE Investigators. Evacetrapib and Cardiovascular Outcomes in High-Risk Vascular Disease. N Engl J Med, 2017; 376: 1933-1942 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Miscellaneous